Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses Pharmacogenomic Technology to Millennium

NEW YORK, Jan. 7-Genaissance Pharmaceuticals has licensed its HAP pharmacogenomic platform to Millennium Pharmaceuticals, the company said today.


The agreement is a non-exclusive, multi-year agreement under which Genaissance will receive license fees from Millennium. Further financial details were not disclosed.


For further information, see the company statement.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.